BMS Investing $400 M in New Sterile Drug-Product Mfg Facility 
By

By
Bristol Myers Squibb (BMS) has announced a $400-million investment at its Dublin, Ireland (Cruiserath) campus for the build and design of a sterile drug-product (SDP) manufacturing facility.   This will be…

BMS Completes $4.1-Bn Acquisition of Radiopharmaceutical Company RayzeBio 
By

By
Bristol Myers Squibb (BMS) has completed its $4,1-billion acquisition of RayzeBio, a San Diego, California-based clinical-stage radiopharmaceutical company, The acquisition was announced in January 2024.  RayzeBio has a position in…

Supplier News: Simtra, CordenPharma, CoreRx & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring Simtra BioPharma Solutions, CordenPharma, CoreRx, Societal CDMO, Ritedose, and Experic.   Formulation Development/Drug Product Manufacturing * Simtra BioPharma To Invest $250 M In Sterile…

Partnering News: Novo Nordisk, AbbVie & More 
By

By
A roundup of bio/pharmaceutical partnering news from Novo Nordisk/Neomorph and AbbVie/OSE Therapeutics.  * Novo Nordisk, Neomorph in $1.46-Bn Molecular Glue Degraders Drug Deal * AbbVie, OSE Therapeutics In $713-M mAb Oncology…

Mfg News: Amgen 
By

By
A roundup of manufacturing news from Amgen. Highlights below.  *  Amgen Opens New Manufacturing Facility in Ohio Amgen Opens New Manufacturing Facility in Ohio Amgen has opened a new manufacturing facility, a…

Daiichi Investing $1.1 Bn In German Site Expansion 
By

By
Daiichi Sankyo plans to invest approximately EUR 1 billion ($1.1 billion) to expand its production and development site in Pfaffenhofen an der Ilm, Germany (north of Munich) into an international…

AstraZeneca Completes $1.2-Bn Acquisition of Cell-Therapy Company Gracell 
By

By
AstraZeneca has completed its acquisition of Gracell Biotechnologies, a Jiangsu, China-based clinical-stage bio/pharmaceutical company focused on cell-therapies, in a deal worth up to $1.2 billion ($1.0 billion upfront and $234…

AstraZeneca Completes $1.1-Bn Acquisition of Vaccine Company Icosavax 
By

By
AstraZeneca has completed its acquisition of Icosavax, a Seattle, Washington-based clinical-stage vaccines company using a protein virus-like particle (VLP) platform, for $1.1 billion ($838 million at closing plus potential contingent…

AbbVie Appoints New CEO 
By

By
AbbVie has announced that its Board of Directors has unanimously selected Robert A. Michael, AbbVie’s current President and Chief Operating Officer, to succeed Richard A. Gonzalez as the company’s chief…

Supplier News: Resilience, Jubilant HollisterStier & More 
By

By
The latest from CDMOs, CMOs, and suppliers featuring National Resilience, Jubilant HollisterStier, Colorcon and Emergent BioSolutions.   Biologics Manufacturing * Colorcon Ventures Invests in Vedanta Biosciences Formulation Development/Drug Product Manufacturing * Resilience Investing $225…